✦ LIBER ✦

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

✍ Scribed by Tural, Deniz; Batur, Sebnem; Erdamar, Sibel; Akar, Emre; Kepil, Nuray; Mandel, Nil Molinas; Serdengeçti, Süheyla

Book ID: 121544609
Publisher: S. Karger AG
Year: 2013
Tongue: English
Weight: 467 KB
Volume: 35
Category: Article
ISSN: 1010-4283
DOI: 10.1007/s13277-013-1138-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of PTEN, BRAF, and EGFR Status

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

✍ Laurent-Puig, P.; Cayre, A.; Manceau, G.; Buc, E.; Bachet, J.-B.; Lecomte, T.; R 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 175 KB

No Survival Benefit from Adding Cetuxima

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis

✍ Zhou, Si-wei; Huang, Yuan-yuan; Wei, Ying; Jiang, Zhi-min; Zhang, Yuan-dong; Yan 📂 Article 📅 2012 🏛 Public Library of Science 🌐 English ⚖ 533 KB

6113 BRAF V600E mutation and Amphireguli

6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

✍ Cremolini, C.; Loupakis, F.; Perrone, G.; Ruzzo, A.; Rulli, E.; Bencardino, K.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

6077 A meta-analysis of the CRYSTAL and

6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status

✍ Van Cutsem, E.; Rougier, P.; Köhne, C.; Stroh, C.; Schlichting, M.; Bokemeyer, C 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Benefit of Adding Panitumumab to FOLFOX4

Benefit of Adding Panitumumab to FOLFOX4 in Patients with KRAS/NRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC): A Number-Needed-To-Treat (NNT) Analysis

✍ Douillard, J.Y.; Sienna, S.; Davison, C.; Braun, S.; Sidhu, R. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB